Y-Intercept (HK)’s Candel Therapeutics CADL Stock Holding History

Y-Intercept (HK)’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-68,472	Closed	-$705K	–	1621
2026 Q2	$705K	Buy	+68,472	New	+$517K	0.01%	1191

Other funds holding CADL

Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s CADL Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Candel Therapeutics (CADL) in Q3 2026, closing a stake of 68,472 shares — an estimated $705K sold.

Y-Intercept (HK) first reported a position in CADL in Q2 2026 and held it in 1 quarter. The position peaked at $705K in Q2 2026. 6 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

Y-Intercept (HK) reported no remaining Candel Therapeutics position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 68,472 Candel Therapeutics shares in Q3 2026, an estimated $705K.
Y-Intercept (HK) first reported a position in Candel Therapeutics in Q2 2026 and held it in 1 quarter.
Y-Intercept (HK)'s Candel Therapeutics position peaked at $705K in Q2 2026.
6 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.